Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolutive pathways

Thea Morris¹, Melanie Stables³, Paul Colville-Nash², Justine Newson³, Geoffrey Bellingan³, Patricia M. de Souza⁴, and Derek W. Gilroy³,¹

¹Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London WC1E 6JJ, United Kingdom; ²South West Thames Institute for Renal Research, St. Helier Hospital, Carshalton SMS 1AA, United Kingdom; ³Critical Care, University College London Hospitals National Health Service Foundation Trust, London NW1 2BU, United Kingdom; and ⁴Cardiothoracic Pharmacology Department, Airway Disease Section, National Heart and Lung Institute, Imperial College, London SW3 6LY, United Kingdom

Edited by Charles N. Serhan, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, and accepted by the Editorial Board March 30, 2010 (received for review January 13, 2010)

Lipoxins (Lxs) and aspirin-triggered epi-Lxs (15-epi-LxA₄) act through the ALX/FPR1 receptor to block leukocyte trafficking, dampen cytokine/chemokine synthesis, and enhance phagocytic clearance of apoptotic leukocytes—key requisites for inflammatory resolution. Although studies using primarily inbred rodents have highlighted resolution as an active event, little is known about the role resolution pathways play in controlling the duration/profile of inflammatory responses in humans. To examine this, we found two types of responders to cantharidin-induced skin blisters in male healthy volunteers: those with immediate leukocyte accumulation and cytokine/chemokine synthesis followed by early resolution and a second group whose inflammation increased gradually over time followed by delayed resolution. In early resolvers, blister 15-epi-LxA₄ and leukocyte ALX were low, but increased as inflammation abated. In contrast, in delayed resolvers, 15-epi-LxA₄ and ALX were high early in the response but waned as inflammation progressed. Elevating 15-epi-LxA₄ in early resolvers using aspirin increased blister leukocyte ALX but reduced cytokines/chemokines as well as polymorphonuclear leukocyte and macrophage numbers. These findings show that two phenotypes exist in humans with respect to inflammation severity/longevity controlled by proresolutive mediators, namely 15-epi-LxA₄. These data have implications for understanding the etiology of chronic inflammation and future directions in antiinflammatory therapy.

I ncreasing numbers of mediators are being identified that switch inflammation off, supporting the notion that inflammatory resolution is an active process (1–3). Of these proresolutive factors, lipoxins (Lxs; e.g., LxA₄/B₄) and epilipoxins (e.g., 15-epi-LxA₄/B₄) are lipids with antiinflammatory and proresolutive properties (4). By signaling through the ALX (FPR1) receptor (5), Lxs reduce cytokine/chemokine synthesis and polymorphonuclear leukocyte (PMN) trafficking as well as enhance phagocytosis of apoptotic leukocytes, thereby facilitating multiple aspects of the resolution cascade. Lxs are formed through three distinct transcellular biosynthetic pathways. The first involves platelet/leukocyte interactions in which leukocyte 5-lipoxygenase (LOX) converts arachidonic acid to the epi-oxide LTA₄, which is released and further transformed by leukocyte-adherent platelets to LxA₄ via the Lx syntheses activity of platelet 12-LOX (6). A second biosynthetic route occurs at the mucosal surfaces by 15-LOX that inserts oxygen into arachidonic acid at carbon 15 to produce 15S-hydroxyeicosatetraenoic acid, which is taken up by PMNs and converted by 5-LOX to Lxs (7, 8). In a third pathway, aspirin triggers epimeric forms of Lxs as a result of acetylation the active site of inducible COX-2 in endothelial or epithelial cells. This results not in the inhibition of COX-2, but in the conversion of arachidonic acid to (15R) hydroxyeicosatetraenoic acid, which is rapidly metabolized in a transcellular manner by leukocyte 5-LOX to 15-epi-LxA₄ or B₄ (9). Interestingly, epi-Lxs are also found in humans under aspirin-free conditions possibly derived from either a cytochrome P450 pathway and/or from an endogenous COX-2–acylating agent capable of generating epi-Lxs in physiological and inflammatory settings (10, 11).

In addition to Lxs, there are a host of other soluble mediators and cells central to resolution whose expression/synthesis occurs at strategic checkpoints throughout inflammation, in which to switch the response off and restore homeostasis (12–17). Although the sequential activation of these proresolutive pathways has almost exclusively been elucidated using inbred rodents, little is known about their role in limiting inflammatory responses in humans. We recently found that cardioprotective doses of aspirin (75 mg; [ASA⁵⁰⁰]) inhibits leukocyte trafficking into cantharidin-induced skin blisters in healthy human volunteers (18). A retrospective analysis of those data revealed that ASA⁵⁰⁰ worked in 60% of individuals in an inflammation-dependent manner, i.e., the more severe the inflammation in terms of leukocyte accumulation, the greater the antiinflammatory effects of ASA⁵⁰⁰, with the remaining volunteers (40%) not responding to aspirin. The baseline temporal profile of cell trafficking in aspirin responders peaked in an immediate early fashion and resolved within a few days (hereafter called early resolvers; [Ers]). Volunteers who were refractory to ASA⁵⁰⁰ had a gradual accumulation of cells that failed to clear the blister site, showing signs of delayed resolution (hereafter called delayed resolvers; [Drvs]). Further analysis showed that interindividual differences in the biosynthesis of endogenous 15-epi-LxA₄ accounted for the differential inflammatory profiles in Drvs versus Ers. Therefore, these data show that acute inflammatory responses in humans follow two distinct profiles controlled, at least in part, by proresolutive pathways. Acquired dysregulation of these protective processes at the genetic level or by antiinflammatory agents with hitherto unappreciated resolution-protective properties (19) may cause ongoing inflammation, tissue injury, or chronic inflammation.

Results

Aspirin Reveals Differential Inflammatory Responses in Humans. We previously found that ASA⁵⁰⁰ was antiinflammatory in 26 male healthy human volunteers in whom it dampened leukocyte traf-
ficking into cantharidin-induced skin blisters (18). Further analysis of those data revealed that volunteers with the most severe inflammation in terms of blister leucocyte numbers exhibited the greatest anti-inflammatory response to ASA<sub>low</sub>. Fig. 1A shows the difference in intrablister total cell numbers before/after aspirin for each volunteer (y axis) against their corresponding baseline cell numbers on the x axis. Therefore, those above 0 on the y axis (16 volunteers) showed a reduction in cells after aspirin (i.e., responders) whereas those on or below 0 on the y axis showed no change or increased cell numbers, respectively (10 volunteers; i.e., nonresponders). Thus, there are two distinct groups of responders to ASA<sub>low</sub>—those with significantly reduced inflammation after treatment (Fig. 1B) and a second group of 10 volunteers who did not respond to ASA<sub>low</sub> (Fig. 1C). Moreover, there was a significant difference in baseline leucocyte numbers at 24 h between responders and nonresponders (Fig. 1D). These data suggest that, following tissue injury, some subjects display a robust inflammatory response conducive to the anti-inflammatory effects of ASA<sub>low</sub> and another group that displays a less severe initial response are refractory to ASA<sub>low</sub>.

**Early Versus Delayed Resolution to Acute Inflammation.** In blisters of volunteers who responded to ASA<sub>low</sub> and who therefore possessed an E<sub>norm</sub> phenotype, there was a peak in total cells at 24 h following cantharidin (solid line, Fig. 2A), with inflammation resolving by 72 h. In contrast, total cell numbers in cantharidin-induced blisters in the remaining 10 volunteers (D<sub>norm</sub>, dotted line, Fig. 2A) was significantly lower at 24 h compared with E<sub>norm</sub> but increased gradually up to 72 h (Fig. 2A). Profiles of CD16b-positive PMNs in Fig. 2B i and CD14-positive monocytes/macrophages (Fig. 2B ii) followed a similar profile to total cells peaking at 24 h in E<sub>norm</sub> and declining thereafter but increasing progressively over time in D<sub>norm</sub>. Representative FACS dot plots are in Fig. 2B iii, showing the change from predominantly CD16b-positive PMNs at 24 h to CD14-positive monocytes/macrophages at resolution using E<sub>norm</sub> as an example. Unlike cells, edema accumulation and clearance followed similar profiles in E<sub>norm</sub> and D<sub>norm</sub> (Fig. 2C). Mirroring leucocyte kinetics, levels of IL-1β were significantly higher in E<sub>norm</sub> versus D<sub>norm</sub> at 24 h (Fig. 2D), with no such differences found with other cytokines and chemokines (Fig. 2 E–L). The results of these experiments reveal two types of responders to acute tissue injury in healthy humans with regard to leucocytes but not edema: the first displayed an early heightened innate immune-mediated response that resolved in an immediate manner, and the second showed a more tempered inflammatory profile that failed to resolve within the timeframe examined (72 h).

**Differences in 15-epi-LxA<sub>4</sub>/ALX Expression Between E<sub>norm</sub> and D<sub>norm</sub>.** Inflammation severity is controlled by a diverse range of endogenous counter-regulatory signals. In this current study, by using cantharidin-induced skin blisters, we found no correlation between levels of anti-inflammatory IL-10 and leucocyte numbers in E<sub>norm</sub> and D<sub>norm</sub>. Similarly, there was no association between leucocyte numbers and levels of prostaglandin E<sub>2</sub>, which exerts inhibitory effects on PMN trafficking via EP2/EP4 receptors by elevating cAMP (20). However, 15-epi-LxA<sub>4</sub> is an endogenous lipid that dampens PMN trafficking (21), proinflammatory cytokine release (ref. 22 and Fig. S1), and facilitates macrophage phagocytosis of apoptotic PMNs (23) through its ALX receptor (5). Levels of blister fluid 15-epi-LxA<sub>4</sub> (Fig. 3A) as well as ALX expression on total cells (Fig. 3B), CD16b-positive PMNs (Fig. 3C), and CD14-positive monocytes/macrophages (Fig. 3D) were significantly lower in E<sub>norm</sub> (solid line, Fig. 3A) compared with D<sub>norm</sub> (dotted line, Fig. 3A) at 24 h but were gradually elevated in E<sub>norm</sub> as inflammation switched off. In contrast, blister fluid 15-epi-LxA<sub>4</sub> (Fig. 3A) and leucocyte ALX expression (Fig. 3B–D) were maximal in D<sub>norm</sub> at 24 h and showed a trend toward a reduction by 72 h coincident with progressively increased cell influx. Representative FACS histograms in Fig. 3C illustrate increased ALX expression on CD16b-positive PMNs in E<sub>norm</sub> compared with D<sub>norm</sub> at 24 h, with similar data as histograms in Fig. 3D illustrating increased ALX expression on CD14-positive monocytes/macrophages at 24 h. Thus, in groups of volunteers who have an enhanced early response to cantharidin, there are correspondingly low levels of 15epi-LxA<sub>4</sub>/ALX that increased in line with leucocyte clearance. In contrast, D<sub>norm</sub> have significantly higher 15epi-LxA<sub>4</sub>/ALX than E<sub>norm</sub> early in the response, but declined as cell numbers increased. Given the anti-inflammatory/resolution properties of epi-Lxs, these data suggest that the dichotomy in response to cantharidin could be caused at least in part by endogenous levels of 15epi-LxA<sub>4</sub> and its receptor expression. The source of 15epi-LxA<sub>4</sub> in humans not taking aspirin is unknown, but mice (not bearing inflammation) given celecoxib have reduced plasma 15epi-LxA<sub>4</sub> whereas levels in animals given SK525A are unchanged (Fig. S2). These data exclude a role for cytochrome 450 in generating endogenous epilipoxins as proposed (11), but suggests the existence of an endogenous factor that acetylates COX-2, resulting in constitutive 15epi-LxA<sub>4</sub> synthesis.

**Modulating 15-epi-LxA<sub>4</sub> and the Inflammatory Response.** As 75 mg aspirin in healthy human volunteers triggers 15epi-LxA<sub>4</sub> synthesis (10) as well as elevates ALX expression (18), we determined whether ASA<sub>low</sub> altered 15epi-LxA<sub>4</sub>/ALX and hence inflammation in E<sub>norm</sub> and D<sub>norm</sub>. Ten days of prophylactic ingestion of 75 mg aspirin, taken orally once daily, in E<sub>norm</sub> (black line, controls; red line, ASA<sub>low</sub>, Fig. 4) increased blister cell–free exudate levels of 15epi-LxA<sub>4</sub> as well as total leucocyte ALX expression (Fig. 4B–D) coincident with
a significant reduction in IL-1β (Fig. 4E) and IL-8 (Fig. 4F) as well as cell numbers (Fig. 4G–I) 24 h following cantharidin. Other cytokines and chemokines were not inhibited (Fig. S3A–H). Equivalent treatment of D²⁰⁰⁻⁻ (black line, controls; red line, ASA low, Fig. 5A) had little effect on 15epi-LxA₄, leukocyte ALX (Fig. 5B–D), IL-1β/IL-8 (Fig. 5 E and F and Fig. S4A–H), or cell numbers (Fig. 5G–I). These data suggest that 15epi-LxA₄ is minimal in Ervs at 24 h and can be elevated above baseline resulting in a dampening of acute inflammatory responses in humans and their differential expression patterns dictate the severity and longevity of acute inflammatory responses.

Discussion

At least two distinct inflammatory events can ensue following cantharidin-induced skin blisters in humans. The first is an immediate response typified by rapid cytokine/chemokine generation and leukocyte influx followed by early resolution (i.e., in E²⁰⁰⁻⁻). The second is a more tempered response characterized by a gradual increase in leukocyte accumulation as well as cytokine/chemokine generation. As inflammation in the latter group did not resolve within the timeframe examined, we called these delayed resolvers (D²⁰⁰⁻⁻). To gain mechanistic insight into the reasons for these differential responses we found that E²⁰⁰⁻⁻ synthesize low quantities of 15-epi-LxA₄ following injury with levels increasing as inflammation abates. In D²⁰⁰⁻⁻, synthesis of 15-epi-LxA₄ is maximal early in the response but declines concomitant with delayed cell accumulation. Given that 15-epi-LxA₄ possesses antiinflammatory and well as proresolution properties, we suggest that 15-epi-LxA₄ acts as an internal braking signal tempering the severity and longevity of acute inflammatory responses in humans. In addition, this study shows that resolution is an active process in healthy individuals and that, unlike rodents, inflammatory responses in humans are at least dichotomous and resolution pathways dictate their longevity and eventual termination. Our findings exclude IL-10 and cAMP-elevating prostaglandin E₂ as factors that could potentially govern the progression and resolution of this cantharidin-induced acute inflammatory response. Furthermore, we did not find any association between inflammation profiles and age or ethnicity. However, we cannot exclude the involvement of other factors, including phagocyte activation-associated molecules such as TGFβ1 (24), apoptosis-inducing factors (e.g., TNF-related apoptosis-inducing ligand) (25), cytokine clearance systems (16, 26), or antiinflammatory signaling pathways (e.g., NF-κB p50/p50) (27).

The criteria for grouping individuals as responders or nonresponders to aspirin arose from our work (18) and that of others (10), which showed that COX-2 acetylation by aspirin generates epixLxs. The rationale was that the more severe the inflammatory response the greater the resultant COX-2 expression and therefore biochemical machinery available for aspirin to make proportionally
more antiinflammatory epi-Lxs (28). Thus, aspirin acts as a type of “magic bullet” exerting its beneficial effects in an inflammation-dependent manner. On this basis, volunteers were grouped according to those who showed a response to aspirin (following cantharidin) and those who did not. Taking this further revealed that responders to aspirin showed a resolution of inflammation more readily than those who were refractory to aspirin. As mentioned earlier, under baseline conditions (i.e., without aspirin), the key determinant of this differential inflammatory profile is 15-epi-LxA4. Importantly, although aspirin was originally shown to trigger epi-Lxs (9), we (18) and others (10) found detectable levels of 15epi-LxA4 in healthy volunteers as well as mice not given aspirin. The source of this non–aspirin-generated epi-Lx is unknown, but it is possible that COX-2 is acetylated by an endogenous acetylating agent to produce 15R-hydroxy eicosatetraenoic acid. Indeed, in mice dosed with COX-2 inhibitors, levels of plasma 15-epi-LxA4 are significantly reduced (Fig. S2). Alternatively, epi-Lxs could be generated by a P450 pathway to produce 15R-hydroxy eicosatetraenoic acid (11). However, given that SKF525A [cytochrome P450 inhibitor selective for CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 but not CYP1A2, CYP2A6, and CYP2E1 (29)] had no effect on plasma epi-Lxs (Fig. S2), we propose that epi-Lxs maybe generated by a cell-derived acetylating agent. Therefore, from the data presented here, we hypothesize that early in the inflammatory response of E<sup>vs</sup>, acetylation of COX-2 is low but increases as inflammation resolves, triggering increases in blister fluid epi-Lx. In contrast, in D<sup>vs</sup>, endogenous COX-2 acetylators generate epi-Lxs early in the response but decline in line with 15-epi-LxA<sub>4</sub> synthesis, taking the “hand brake” off inflammation. This endogenous acetylating hypothesis would certainly explain why aspirin failed to trigger 15-epi-LxA<sub>4</sub> in D<sup>vs</sup> as the inflammatory milieu would be saturated and the addition of an exogenous acetylating agent (i.e., aspirin) would fail to further acetylate COX-2.

In our original study, ASA<sub>low</sub> did not affect blister fluid cytokine levels in 26 volunteers despite triggering 15-epi-LxA<sub>4</sub>. This was surprising given that 15-epi-LxA<sub>4</sub> inhibits cytokine and chemokine release from experimental tissue injury (30) and isolated cells stimulated in culture (31). Indeed, we found that 15-epi-LxA<sub>4</sub> inhibited a range of cytokines/chemokines from LPS-stimulated human monocytes, monocyte-derived macrophages, and human umbilical vein endothelial cells (HUVECs), with the most broad-ranging suppressive effects being on monocytes (Fig. S1). However, the presence of a group of individuals who are refractory to ASA<sub>low</sub> among those sensitive to ASA<sub>low</sub> provided the erroneous impression of an overall null effect. Separating groups based on inflammation severity/longevity revealed that those with low baseline 15-epi-LxA<sub>4</sub> and therefore high in inflammation responded to ASA<sub>low</sub> because it triggered 15-epi-LxA<sub>4</sub> and therefore high inflammation responded to ASA<sub>low</sub> because it triggered 15-epi-LxA<sub>4</sub>/ALX and therefore dampened cytokines/chemokines and leukocyte trafficking. D<sup>vs</sup> had low cytokine/chemokine levels as a result of maximum baseline 15-epi-LxA<sub>4</sub>/ALX.

As the latter was not further elevated by ASA<sub>low</sub>, these D<sup>vs</sup> were ASA<sub>low</sub>-refractory. This does not exclude the likelihood that D<sup>vs</sup> may become responsive to ASA<sub>low</sub> when baseline 15-epi-LxA<sub>4</sub>/ALX eventually wanes and cytokine/chemokine levels increase. How-

---

**Fig. 3.** The 15-epi-LxA<sub>4</sub> and its ALX receptor dictate inflammation severity and longevity in humans with acute inflammation. Of the endogenous antiinflammatory and proresolution factors measured over time (in h), significant differences were found only in levels of blister fluid 15-epi-LxA<sub>4</sub> (A) as well as ALX expression on total blister leukocyte (B), CD16b-positive PMNs (C), and CD14-positive monocytes/macrophages (D) between E<sup>vs</sup> (solid line) and D<sup>vs</sup> (dotted line). (C) Representative FACs histograms illustrate increased ALX expression on CD16b-positive PMNs in E<sup>vs</sup> compared with D<sup>vs</sup> with similar comparative histograms (D) illustrating increased ALX expression on CD14-positive monocytes/macrophages. Data are presented as mean ± SEM; *P < 0.05 and ***P < 0.001 represent differences in inflammatory parameters between E<sup>vs</sup> and D<sup>vs</sup> at 24 h. AU represents arbitrary units of ALX expression intensity determined by FACs.
ever, we did not examine the long-term fate of inflammation/resolution in Δ^νΔ because of the inherent instability of their blisters. We were also unaware of how long inflammation lasts in these responders and what proresolution pathways are required to ultimately dampen their response.

This is one of the first reports showing that modulating a proresolution pathway dampens innate immune-mediated responses in healthy humans. These individuals did not take fish oil, nor did they have their diet supplemented with docosahexaenoic acid, a precursor that, when metabolized instead of arachidonic acid down the LOX/COX pathway in the presence of aspirin, results in the generation of lipids of the resolvin D series, which dampen PMN trafficking into and clear macrophages out of sites of inflammation (32). Given the broad antiinflammatory, proresolution, and antibacterial properties of resolvins (33), it would be important to examine the effects of fish oils in general, or docosahexaenoic acid in particular, with aspirin for their combined antiinflammatory, antibacterial, and cardioprotective effects in man. That notwithstanding, ASA^low has been associated with gastric bleeding, and its usefulness as a cardioprotective agent balanced against gastrointestinal side effects is of ongoing concern (34). Therefore, next generation epi-Lxs, which protect the gastric mucosa from injury (35), as well as resolvins, may replace parental aspirin as novel antiinflammatory/cardioprotective agents with reduced side effects.

In summary, we have shown that inflammation progresses at a different rate and with different degrees of severity in human skin blisters arising from differentially expressed proresolution pathways. And although this could be result from different secretion rates of proinflammatory signals (e.g., cytokines/chemokines, cell adhesion molecules), we propose that, as inflammation is tightly regulated to prevent it becoming “overexuberant,” the control of inflammation is tempered by endogenous checkpoint control systems including epi-Lxs. This system is differentially expressed in different populations, resulting in different degrees of inflammation severity and longevity. Arguably, this could impact the rate at which different populations neutralize bacterial infection, for instance, or the propensity to develop chronic inflammation/autoimmunity arising from a more sustained response. Indeed, there is an inverse correlation between levels of endogenous lipoxins and disease severity in severe asthma (36), Henoch–Schönlein purpura (37), and scleroderma lung disease (38). Our findings may explain, in general, why some individuals are refractory to conventional antiinflammatory agents and importantly emphasizes the need to tailor antiinflammatory treatment regimes to individuals depending on their rate/profile of inflammatory response. These data also highlight that, when developing antiinflammatory drugs, we need to be mindful of their potentially resolution-toxic properties, i.e., their ability to subvert the body’s attempts to switch off inflammation.

Materials and Methods

Inflammatory Models and Drug Treatment. Two blisters were elicited on the ventral aspect of the forearms of male healthy volunteers (aged 25–50 y) as previously described (39–42) by applying 10 μL of 0.1% Cantharone (Dormer Labs). Volunteers were of diverse ethnic backgrounds and were not taking NSAIDs or aspirin-containing medications for 2 weeks before commencement of the study. ASA^low (75 mg) was taken daily for 10 d before a second set of blisters was elicited on the contralateral forearm, with aspirin consumed for the duration of the response up to 72 h. Ethical approval was obtained from UCL Ethics (project identification no. 1309/001). Blister cell numbers were enumerated by hemocytometer. For plasma lipid measurements, animals were bred under standard conditions and maintained in a 12-h/12-h light/dark
cycle at 22 ± 1 °C and given food and tap water ad libitum in accordance with United Kingdom Home Office regulations.

**FACS and Lipid Mediators.** Anti-CD14, CD16b, and ALX (human) as well as isotype controls were from Seroptic or BD Biosciences. Peripheral blood and blister-derived leukocytes were acquired by FACS-Calibur (BD Biosciences) using appropriate compensation when necessary, and data were analyzed by CellQuest Pro. Thromboxane A2 in the form of stable thromboxane B2 was measured by enzyme immunoassay (GE Healthcare) and 15-epi-LxA4 was measured by ELISA (Neogen). Cytokines and chemokines were measured by Multiplex cytokine array analysis (Bio-Rad) using the manufacturer’s protocols.

**Leukocyte Isolation, in Vitro Cell Culturing, and Treatment Protocols.** Blood (80 mL) was collected in heparin from healthy male volunteers followed by red blood cell sedimentation using E洛HAS. Remaining leukocyte-rich plasma was subjected to Percoll density gradient centrifugation to separate monocytes into fractions (1 × 10^6 cells) were incubated overnight and washed to remove nonadherent leukocytes. For differentiation into macrophages, monocytes were cultured in RPMI 1640 without/without LPS (1 μg/mL, 1 h before stimulation). HUVECs (human umbilical endothelial cells) were cultured with LPS (1 μg/mL) for 1 h were treated with 0.3 μg/mL 15-epi-LxA4 (Calbiochem) for a further 24 h.

**Statistical Analysis.** Data were analyzed using the two-tailed paired Student t test for normally distributed data, with P < 0.05 being considered significant. All analyses were paired Student t tests. Wilcoxon matched-pairs test was used to analyze data standardized to the number of cells accumulated within the blister (15-epi-LxA4/10^6 cells); because it did not follow a Gaussian distribution, P < 0.05 was considered significant. When comparing two groups with unequal variances, a two-tailed unpaired t test with the Welch correction was used. For animal studies and in vitro assays, data were analyzed by ANOVA followed by Bonferroni test.

**ACKNOWLEDGMENTS.** D.W.G. is a Wellcome Trust funded Senior Research Fellow. G.B. acknowledges support from University College London Hospital University College London and the Department of Health National Institute for Health Research Biomedical Research Centers funding scheme. This work was funded by the United Kingdom Wellcome Trust and Medical Research Council (D.W.G.).
Fig. S1. Inhibitory effect of 15-epi-LxA_4 on inflammatory cytokine/chemokine synthesis from LPS-stimulated human monocytes (A), monocyte-derived macrophages (B), and HUVECs (C). Data are presented as mean ± SEM; *P < 0.05 and **P < 0.01.
Fig. S2. Plasma levels of 15-epi-LxA$_4$ are inhibited by COX inhibition in naive animals. Naproxen and celecoxib were dosed at 10 mg/kg for 3 d, followed by plasma measurements of TxB$_2$ (A), the active metabolite of TxA$_2$; and 15-epi-LxA$_4$ (B). (C) No effect on plasma 15-epi-LxA$_4$ was found with the cytochrome P450 inhibitor SKF525A (twice daily for 3 d at 30 mg/kg). Data were analyzed by ANOVA followed by Bonferroni t test and presented as mean ± SEM; *P < 0.05.
Fig. S3. Whereas ASA<sub>low</sub> (solid red line) inhibited IL-1β and IL-8 in the blister fluid of volunteers possessing an early resolving phenotype (Fig. 4 E and F in the main text), it had a trend toward but no significant reduction in levels of a range of inflammatory cytokines (A–G) and blister edema (H). Black solid line represents controls.
In addition to having no effect on blister IL-1β and IL-8 (Fig. 5 A–F in the main text), ASAlow (dotted red line) was also without effect on a range of inflammatory cytokines (A–G) and edema (H) in volunteers with a delayed resolving phenotype. Black solid line represents controls.